Log in

Starpharma Holdings Limited (SPL.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$1.00
52-Week Range N/A
Volume351,391 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.79 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales$6.62 million
Book ValueA$0.08 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive SPL News and Ratings via Email

Sign-up to receive the latest news and ratings for SPL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Starpharma Holdings Limited (SPL.AX) (ASX:SPL) Frequently Asked Questions

What stocks does MarketBeat like better than Starpharma Holdings Limited (SPL.AX)?

Wall Street analysts have given Starpharma Holdings Limited (SPL.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Starpharma Holdings Limited (SPL.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Starpharma Holdings Limited (SPL.AX)'s earnings last quarter?

Starpharma Holdings Limited (SPL.AX) (ASX:SPL) issued its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.02) earnings per share for the quarter.
View Starpharma Holdings Limited (SPL.AX)'s earnings history

Who are some of Starpharma Holdings Limited (SPL.AX)'s key competitors?

What other stocks do shareholders of Starpharma Holdings Limited (SPL.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Starpharma Holdings Limited (SPL.AX) investors own include Allena Pharmaceuticals (ALNA), Aurora Cannabis (ACBFF), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Amira Nature Foods (ANFI), Apellis Pharmaceuticals (APLS) and Aquantia (AQ).

Who are Starpharma Holdings Limited (SPL.AX)'s key executives?

Starpharma Holdings Limited (SPL.AX)'s management team includes the following people:
  • Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 57, Pay $579.15k)
  • Mr. Nigel J. Baade B.Com, Grad. Dip., CPA, CFO & Company Sec.

What is Starpharma Holdings Limited (SPL.AX)'s stock symbol?

Starpharma Holdings Limited (SPL.AX) trades on the ASX under the ticker symbol "SPL."

How big of a company is Starpharma Holdings Limited (SPL.AX)?

Starpharma Holdings Limited (SPL.AX) has a market capitalization of $0.00 and generates $6.62 million in revenue each year.

What is Starpharma Holdings Limited (SPL.AX)'s official website?

The official website for Starpharma Holdings Limited (SPL.AX) is www.starpharma.com.

How can I contact Starpharma Holdings Limited (SPL.AX)?

Starpharma Holdings Limited (SPL.AX)'s mailing address is 4-6 Southampton Cres, MELBOURNE, VIC 3067, Australia. The company can be reached via phone at +61-3-85322700.

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.